{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:13:43Z","timestamp":1760235223523,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["FP15BA"],"award-info":[{"award-number":["FP15BA"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Resistance-associated substitutions (RASs) may exist prior to treatment and contribute to the failure of treatment with direct-acting antivirals (DAAs). As the major site of HCV replication, naturally occurring variants with RASs may segregate into the liver. In the present study, we performed viral population sequencing to retrospectively investigate the NS3 and NS5A RAS profiles in 34 HIV\/HCV coinfected patients na\u00efve to anti-HCV treatment who underwent diagnostic liver biopsy between 2000 and 2006 and had liver and plasma samples available. Sixteen were infected by HCV genotype (GT) 1a, 11 by GT3a, and 7 by GT4d. The analysis of the NS3 domain in GT1a showed a difference in strain between the liver and plasma in three cases, with a preponderance of specific RASs in the liver compartment. In GT4d samples, 6\/7 coupled liver and plasma samples were concordant with no RASs. Sequence analysis of the NS5A domain showed the presence of RASs in the livers of 2\/16 patients harboring GT1a but not in the corresponding plasma. In GT4d, NS5A RASs were detected in 7\/7 liver tissues and 5\/7 plasma samples. NS3 domain and NS5A domain were found to be conserved in plasma and livers of patients infected with GT3a. Thus, RASs within GT1a and GT4d more likely segregate into the liver and may explain the emergence of resistant strains during DAA treatment.<\/jats:p>","DOI":"10.3390\/v13081486","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T02:18:24Z","timestamp":1627525104000},"page":"1486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Compartmentalization of Resistance-Associated Substitutions in HIV\/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-5376","authenticated-orcid":false,"given":"Giulia","family":"Morsica","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Vercesi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Hasson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Messina","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9138","authenticated-orcid":false,"given":"Caterina","family":"Uberti-Foppa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"},{"name":"Faculty of Medicine and Surgery, Vita-Salute University, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Bagaglio","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Scientific Institute Ospedale San Raffaele, 20132 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"ref_1","unstructured":"WHO (2017). Global Hepatitis Report 2017, World Health Organization. Report No.: 9241565454."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: A global systematic review and meta-analysis","volume":"16","author":"Platt","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nu\u00f1ez, J.A.P., Gonzalez-Garcia, J., Berenguer, J., Gallego, M.J.V., Loyarte, J.A.I., Metola, L., Bernal, E., Navarro, G., Del Amo, J., and Jarr\u00edn, I. (2018). Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients. Medicine, 97.","DOI":"10.1097\/MD.0000000000012238"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s10620-018-5215-0","article-title":"Similar sustained virologic response in real-world and clinical trial studies of hepatitis c\/human immunodeficiency virus coinfection","volume":"63","author":"Sikavi","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1080\/09540121.2019.1645808","article-title":"Real life results of direct acting antiviral therapy for HCV infection in HIV\u2013HCV-coinfected patients: Epi-Ter2 study","volume":"32","author":"Piekarska","year":"2019","journal-title":"AIDS Care"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Patel, S.V., Jayaweera, D.T., Althoff, K.N., Eron, J.J., Radtchenko, J., Mills, A., Moyle, G., Santiago, S., Sax, P.E., and Gillman, J. (2020). Real-world efficacy of direct acting antiviral therapies in patients with HIV\/HCV. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228847"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2019.09.011","article-title":"Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia","volume":"120","author":"Papaluca","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jvh.12503","article-title":"NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-na\u00efve subjects","volume":"23","author":"Vidal","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.2147\/IDR.S179158","article-title":"Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents","volume":"11","author":"Minosse","year":"2018","journal-title":"Infect. Drug Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of Resistance-Associated Substitutions in Patients with Chronic HCV Infection Following Treatment With Direct-Acting Antivirals","volume":"154","author":"Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kyuregyan, K.K., Kichatova, V., Karlsen, A.A., Isaeva, O.V., Solonin, S.A., Petkov, S., Nielsen, M., Isaguliants, M.G., and Mikhailov, M.I. (2020). Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicine, 8.","DOI":"10.3390\/biomedicines8040080"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3851\/IMP2326","article-title":"Raimondo, GNS3 genetic variability in HCV genotype-1b isolates from liver specimens and blood samples of treatment-naive patients with chronic hepatitis C","volume":"18","author":"Maimone","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00705-017-3341-1","article-title":"NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B","volume":"162","author":"Morsica","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/liv.14168","article-title":"HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma","volume":"39","author":"Sorbo","year":"2019","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bagaglio, S., Hasson, H., Peano, L., Vercesi, R., Messina, E., Galli, A., Uberti-Foppa, C., and Morsica, G. (2020). A prospective Italian study on baseline NS3 and NS5A resistance to direct-acting antivirals in a real-world setting of HIV-1\/HCV coinfected patients and association with treatment outcome. Viruses, 12.","DOI":"10.3390\/v12030269"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","article-title":"The CLUSTAL_X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools","volume":"25","author":"Thompson","year":"1997","journal-title":"Nucl. Acids Res."},{"key":"ref_20","unstructured":"Felsenstein, J. (1993). PHYLIP (Phylogeny Inference Package) Version 3.5c, Department of Genetics, University of Washington. Distributed by the Author."},{"key":"ref_21","first-page":"357","article-title":"Treeview: An application to display phylogenetic trees on personal computers","volume":"12","author":"Page","year":"1996","journal-title":"Comput. Appl. Biosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jmv.24971","article-title":"Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients","volume":"90","author":"Carrasco","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Stelzl, E., Haas, B., Bauer, B., Zhang, S., Fiss, E.H., Hillman, G., Hamilton, A.T., Mehta, R., Heil, M.L., and Marins, E.G. (2017). First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181273"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:36:31Z","timestamp":1760164591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/8\/1486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["v13081486"],"URL":"https:\/\/doi.org\/10.3390\/v13081486","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2021,7,29]]}}}